Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0282726 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, 2023. Verfasst von Yu Xiong und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China. Hauptthemen laut MEDLINE: Antifibrinolytic Agents, Brain Injuries, Traumatic, Hydrocephalus, Subarachnoid Hemorrhage. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although some studies have shown that tranexamic acid is beneficial to patients with intracranial haemorrhage, the efficacy and safety of tranexamic acid for intracranial haemorrhage remain controversial.
Method
The PubMed, EMBASE, and Cochrane Library databases were systematically searched. The review followed PRISMA guidelines. Data were analyzed using the random-effects model.
Results
Twenty-five randomized controlled trials were included. Tranexamic acid significantly inhibited hematoma growth in intracranial hemorrhage (ICH) and traumatic brain injury (TBI) patients. (ICH: mean difference -1.76, 95%CI -2.78 to -0.79, I 2 = 0%, P < .001; TBI: MD -4.82, 95%CI -8.06 to -1.58, I 2 = 0%, P = .004). For subarachnoid hemorrhage (SAH) patients, it significantly decreased the risk of hydrocephalus (OR 1.23, 95%CI 1.01 to 1.50, I 2 = 0%, P = .04) and rebleeding (OR, 0.52, 95%CI 0.35 to 0.79, I 2 = 56% P = .002). There was no significance in modified Rankin Scale, Glasgow Outcome Scale 3–5, mortality, deep vein thrombosis, pulmonary embolism, or ischemic stroke/transient ischemic.
Conclusion
Tranexamic acid can significantly reduce the risk of intracranial haemorrhage growth in patients with ICH and TBI. Tranexamic acid can reduce the incidence of complications (hydrocephalus, rebleeding) in patients with SAH, which can indirectly improve the quality of life of patients with intracranial haemorrhage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China.
- Department of Neurology, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, Fujian Province, China.
- Department of Neurosurgery, Center for Neurosurgery, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
- 2nd Department of Neurosurgery, "Attikon" University Hospital, National and Kapodistrian University, Athens Medical School, Athens, Greece.
- Neurosurgery, Metropolitan Hospital, Athens, Greece.
- Centre of Neurological and Metabolic Research, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
ORCID-Profile: Feng Zheng
Zitieren
APA
Xiong, Y., Guo, X., Huang, X., Kang, X., Zhou, J., Chen, C., Pan, Z., Wang, L., Goldbrunner, R., Stavrinou, L., Stavrinou, P., Lin, S., Chen, Y., Hu, W., & Zheng, F. (2023). Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0282726
Vancouver
Xiong Y, Guo X, Huang X, Kang X, Zhou J, Chen C, et al. Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis. PLOS ONE. 2023. doi:10.1371/journal.pone.0282726
BibTeX
@article{Xiong2023,
author = {Xiong, Yu and Guo, Xiumei and Huang, Xinyue and Kang, Xiaodong and Zhou, Jianfeng and Chen, Chunhui and Pan, Zhigang and Wang, Linxing and Goldbrunner, Roland and Stavrinou, Lampis and Stavrinou, Pantelis and Lin, Shu and Chen, Yuping and Hu, Weipeng and Zheng, Feng},
title = {Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0282726}
}
EUVIMED